Triple-negative breast cancers are of current interest, and probably will be so in the near future. Therapeutically relevant subgroups of these cancers are increasingly being recognized, and therapies are being developed to deal with them. These novel therapies are not targeting triple-negative tumors uniquely, but rater targeting the more unfavorable subgroups. Some triple-negative cancers have very good prognosis if pathologically complete response can be obtained after chemotherapy. At the present time neoadjuvant chemotherapy provides a way to distinguish favorable from unfavorable subgroups.
